Active Ingredient(s): Ranibizumab
FDA Approved: * June 30, 2006
Pharm Company: * GENENTECH
Category: Vision / Eye Health

Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic[7] that is approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion. Ranibizumab was developed by Genentech and marketed by them in the United States, an... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Lucentis 10 mg/ml Intravitreal Injection, Solution
NDC: 50242-080
Genentech, Inc.
Lucentis 6 mg/ml Intravitreal Injection, Solution
NDC: 50242-082
Genentech, Inc.

Related Brands

Drugs with the same active ingredients

Popular Topics

Avastin/ lucentis side effecis

After eye injections of avastin i was switched to lucentis. i then had 2 tia's and stopped treatment. I had been exp...

macugen lucentis

masculen degeneration...